{
    "clinical_study": {
        "@rank": "41930", 
        "arm_group": {
            "arm_group_label": "Treatment (trametinib, Akt inhibitor GSK2141795)", 
            "arm_group_type": "Experimental", 
            "description": "PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression continue to Part 2.\nPART 2: Patients receive trametinib as in Part 1 and also receive Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well trametinib and v-akt murine thymoma viral oncogene\n      homolog 1 (Akt) inhibitor GSK2141795 work in treating patients with metastatic\n      triple-negative breast cancer. Trametinib and Akt inhibitor GSK2141795 may stop the growth\n      of tumor cells by blocking some of the enzymes needed for cell growth."
        }, 
        "brief_title": "Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer", 
        "condition": [
            "Estrogen Receptor-negative Breast Cancer", 
            "HER2-negative Breast Cancer", 
            "Male Breast Cancer", 
            "Progesterone Receptor-negative Breast Cancer", 
            "Recurrent Breast Cancer", 
            "Stage IV Breast Cancer", 
            "Triple-negative Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Breast Neoplasms, Male"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To assess the anti-tumor activity associated with trametinib monotherapy in patients with\n      triple negative breast cancer (TNBC).\n\n      SECONDARY OBJECTIVES:\n\n      I. To assess the anti-tumor activity associated with trametinib in combination with AKT\n      inhibitor GSK2141795 after progression on trametinib in patients with metastatic TNBC.\n\n      II. To determine the progression-free survival following the initiation of treatment with\n      trametinib monotherapy in patients with metastatic TNBC.\n\n      III. To determine the progression-free survival following the initiation of treatment with\n      trametinib in combination with GSK2141795 in patients with metastatic TNBC.\n\n      IV. To determine the overall survival following the initiation of treatment with trametinib\n      with GSK214179 in patients with metastatic TNBC.\n\n      V. To determine the nature and degree of toxicities associated with trametinib monotherapy\n      and trametinib in combination with GSK2141795 in patients with metastatic TNBC.\n\n      VI. To determine the biomarker potential of phosphatase and tensin homolog (PTEN) to predict\n      response to single agent trametinib.\n\n      VII. To determine molecular markers of sensitivity and resistance to trametinib monotherapy\n      and trametinib in combination with GSK2141795 in patients with metastatic TNBC.\n\n      OUTLINE:\n\n      PART 1: Patients receive trametinib orally (PO) once daily (QD) on days 1-28. Courses repeat\n      every 28 days in the absence of disease progression or unacceptable toxicity. Patients who\n      experience disease progression continue to Part 2.\n\n      PART 2: Patients receive trametinib as in Part 1 and also receive Akt inhibitor GSK2141795\n      PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or\n      unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up for 52 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically or cytologically confirmed metastatic invasive\n             breast cancer that is negative for the estrogen receptor (ER), progesterone receptor\n             (PR) and human epidermal growth factor 2 (HER2) by institutional guidelines\n\n          -  Patients must have measurable disease (Response Evaluation Criteria in Solid Tumors\n             version 1.1 [RECIST 1.1])\n\n          -  Patients must have had exposure to at least 1 and no more than 3 prior chemotherapy\n             regimens for the treatment of metastatic breast cancer\n\n          -  Patients must consent to both a pretreatment and a post-treatment mandatory research\n             biopsy prior to enrolling on trial, and therefore, must have tissue (excluding bone\n             or brain) that is amenable to biopsy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\n          -  Life expectancy of greater than 3 months\n\n          -  Able to swallow and retain orally administered medication and does not have any\n             clinically significant gastrointestinal abnormalities that may alter absorption such\n             as malabsorption syndrome or major resection of the stomach or bowels\n\n          -  All prior treatment-related toxicities must be Common Terminology Criteria for\n             Adverse Events version 4 (CTCAE v4) grade =< 1 (except alopecia) at the time of\n             enrollment\n\n          -  Absolute neutrophil count >= 1,500/mcL\n\n          -  Platelets >= 75,000/mcL\n\n          -  Total bilirubin =< 1.5 \u00d7 institutional upper limit of normal\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 2.5 \u00d7 institutional upper limit of normal\n\n          -  Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by\n             echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)\n\n          -  Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockroft-Gault\n             formula) >= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min\n\n          -  Patients must have controlled blood pressure with a systolic blood pressure < 140\n             mmHg and diastolic < 90 mmHg; anti-hypertensive medications are permitted\n\n          -  Patients must be at least 4 weeks from last radiation dose; patients must be at least\n             4 weeks from last chemotherapy, targeted therapy, or biologic therapy; patients must\n             be at least 4 weeks from last surgical procedure and recovered from all\n             post-operative complications\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) prior to study entry and\n             for the duration of study participation; should a woman become pregnant or suspect\n             she is pregnant while she or her partner is participating in this study, she should\n             inform her treating physician immediately; men treated or enrolled on this protocol\n             must also agree to use adequate contraception prior to the study, for the duration of\n             study participation, and 4 months after completion of trametinib monotherapy or in\n             combination with GSK2141795 administration\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  History of another malignancy\n\n               -  Exception: Patients who have been disease-free for 3 years, or patients with a\n                  history of completely resected non-melanoma skin cancer and/or patients with\n                  indolent secondary malignancies, are eligible\n\n          -  History of interstitial lung disease or pneumonitis\n\n          -  History of type I diabetes mellitus; if a patient has type II diabetes, they must\n             have a glycosylated hemoglobin (hemoglobin A1C) =< 8%; patients with a screening\n             fasting glucose > 120 mg/dL will be excluded\n\n          -  Uncontrolled hypothyroidism; patients must have a normal thyroid-stimulating hormone\n             (TSH) per institutional standards at baseline\n\n          -  Patients who are receiving any other investigational agents\n\n          -  Individuals with symptomatic or progressive brain metastases are ineligible; subjects\n             with treated brain metastases are eligible if they have no radiographic or other\n             signs of progression in the brain for >= 3 weeks after completion of local therapy;\n             any corticosteroid use for brain metastases must have been discontinued without the\n             subsequent appearance of symptoms for >= 3 weeks prior to study enrollment\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to trametinib monotherapy or trametinib in combination with GSK2141795\n\n          -  Current use of a prohibited medication; the following medications or non-drug\n             therapies are prohibited:\n\n               -  Other anti-cancer therapy while on study treatment (megestrol if used as an\n                  appetite stimulant is allowed)\n\n               -  The concurrent use of all herbal supplements is prohibited during the study\n                  (including, but not limited to, St. John's wort, kava, ephedra [ma huang],\n                  gingko biloba, yohimbe, saw palmetto, or ginseng)\n\n               -  Patients receiving strong inhibitors or inducers of cytochrome P450, family 3,\n                  subfamily A, polypeptide 4 (CYP3A4) are ineligible\n\n          -  History or current evidence/risk of retinal vein occlusion (RVO) or central serous\n             retinopathy (CSR) or predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma\n             or ocular hypertension, uncontrolled hypertension, history of hyperviscosity or\n             hypercoagulability syndromes; visible retinal pathology as assessed by ophthalmic\n             exam that is considered a risk factor for RVO or CSR such as evidence of new optic\n             disc cupping, evidence of new visual field defects, and intraocular pressure > 21 mm\n             Hg\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Pregnant women are excluded from this study, breastfeeding should be discontinued if\n             the mother is treated with trametinib monotherapy or trametinib in combination with\n             GSK2141795\n\n          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral\n             therapy are ineligible"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964924", 
            "org_study_id": "NCI-2013-01895", 
            "secondary_id": [
                "NCI-2013-01895", 
                "2013C0069", 
                "NCI 9455", 
                "OSU 13117", 
                "9455", 
                "N01CM00070", 
                "P30CA016058"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (trametinib, Akt inhibitor GSK2141795)", 
                "description": "Given PO", 
                "intervention_name": "trametinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GSK1120212", 
                    "JTP-74057", 
                    "Mekinist"
                ]
            }, 
            {
                "arm_group_label": "Treatment (trametinib, Akt inhibitor GSK2141795)", 
                "description": "Given PO", 
                "intervention_name": "Akt inhibitor GSK2141795", 
                "intervention_type": "Drug", 
                "other_name": "GSK2141795"
            }, 
            {
                "arm_group_label": "Treatment (trametinib, Akt inhibitor GSK2141795)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 9, 2014", 
        "location": [
            {
                "contact": {
                    "email": "isaacsc@georgetown.edu", 
                    "last_name": "Claudine Isaacs", 
                    "phone": "202-444-3677"
                }, 
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20057"
                    }, 
                    "name": "Lombardi Comprehensive Cancer Center at Georgetown University"
                }, 
                "investigator": {
                    "last_name": "Claudine Isaacs", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Susan.minton@moffitt.org", 
                    "last_name": "Susan E. Minton", 
                    "phone": "813-745-3806"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center and Research Institute"
                }, 
                "investigator": {
                    "last_name": "Susan E. Minton", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Ellis.levine@roswellpark.org", 
                    "last_name": "Ellis G. Levine", 
                    "phone": "716-845-2300"
                }, 
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263"
                    }, 
                    "name": "Roswell Park Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Ellis G. Levine", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kreeder@med.unc.edu", 
                    "last_name": "Katherine E. Reeder-Hayes", 
                    "phone": "919-966-0766"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "University of North Carolina"
                }, 
                "investigator": {
                    "last_name": "Katherine E. Reeder-Hayes", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Lyndsay.harris@uhhospitals.org", 
                    "last_name": "Lyndsay N. Harris", 
                    "phone": "216-286-4414"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Case Western Reserve University"
                }, 
                "investigator": {
                    "last_name": "Lyndsay N. Harris", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "buddg@ccf.org", 
                    "last_name": "George T. Budd", 
                    "phone": "216-444-6480"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Foundation"
                }, 
                "investigator": {
                    "last_name": "George T. Budd", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "erin.olson@osumc.edu", 
                    "last_name": "Erin M. MaCrae", 
                    "phone": "614-366-8541"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Erin M. MaCrae", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "julie.means@vanderbilt.edu", 
                    "last_name": "Julie A. Means-Powell", 
                    "phone": "615-936-3524"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt-Ingram Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Julie A. Means-Powell", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "apoklepovic@mcvh-vcu.edu", 
                    "last_name": "Andrew Poklepovic", 
                    "phone": "804-628-2321"
                }, 
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23298"
                    }, 
                    "name": "Virginia Commonwealth University"
                }, 
                "investigator": {
                    "last_name": "Andrew Poklepovic", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer", 
        "other_outcome": [
            {
                "description": "Ratios between tumors sampled prior to initiating trametinib single agent treatment and at time of progression (TOP) on either single agent trametinib or the combination (TOP/pre-treat ratio), will be calculated. These ratios will be median-centered and clustered using Cluster 2.0 software. Student's t-test for differences between average protein intensity ratios at these intervals will be calculated using Microsoft Excel by grouping all the ratios for individual clusters.", 
                "measure": "Protein intensity fold-change ratios assessed by reverse phase protein assay (RPPA) intensity values", 
                "safety_issue": "No", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "measure": "Predictive value of PTEN and other biomarkers on patient outcome (survival, ORR, and CBR)", 
                "safety_issue": "No", 
                "time_frame": "At time of disease progression, assessed up to 52 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "Ohio State University", 
            "last_name": "Erin MaCrae", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Exact binomial 95% confidence intervals for the true PR+CR response rate will be calculated.", 
            "measure": "Objective response rate (ORR), defined as the proportion of patients who have had a partial response (PR) or complete response (CR) (RECIST 1.1 based) within the first 6 months after initiation of therapy with trametinib", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964924"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The Kaplan-Meier method will be used to estimate overall survival distribution.", 
                "measure": "Overall survival (Part 2)", 
                "safety_issue": "No", 
                "time_frame": "Start date of the treatment to the date of the event (i.e., death) or the date of last follow-up to evaluate that event, assessed up to 52 weeks"
            }, 
            {
                "description": "The Kaplan-Meier method will be used to estimate progression-free survival distribution.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "The duration of time from start of treatment to time of progression or death, whichever comes first, assessed up to 52 weeks"
            }, 
            {
                "description": "The methods of Kaplan and Meier will be used to evaluate this.", 
                "measure": "Duration of objective response", 
                "safety_issue": "No", 
                "time_frame": "Date of documentation of response to the date of progression and/or death, assessed up to 52 weeks"
            }, 
            {
                "measure": "Clinical benefit rate (CBR = CR+PR+stable disease [SD])", 
                "safety_issue": "No", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "description": "The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. All adverse event data that are graded as 3, 4, or 5 and classified as either \"unrelated\" or \"unlikely to be related\" to study treatment will be reviewed in the event of an actual relationship developing.", 
                "measure": "Incidence of adverse events that are classified as either possibly, probably, or definitely related to study treatment graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "measure": "Incidence of severe (grade 3+) adverse events or toxicities graded per NCI CTCAE version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "measure": "Tolerability of the regimen defined as the number of patients who required dose modifications and/or dose delays", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "measure": "Proportion of patients who go off treatment due to adverse reactions", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "measure": "Proportion of patients who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}